Breaking News Instant updates and real-time market news.

TIF

Tiffany

$83.25

5.11 (6.54%)

, SYK

Stryker

$116.17

3.22 (2.85%)

09:55
11/29/16
11/29
09:55
11/29/16
09:55

Early notable gainers among liquid option names on November 29th

Notable gainers among liquid option names this morning include Tiffany (TIF) $83.59 +5.43, Stryker (SYK) $116.02 +3.04, UnitedHealth (UNH) $156.05 +3.91, Allergan (AGN) $193.91 +3.89, and Digital Realty (DLR) $93.21 +1.71.

TIF

Tiffany

$83.25

5.11 (6.54%)

SYK

Stryker

$116.17

3.22 (2.85%)

UNH

UnitedHealth

$156.49

4.38 (2.88%)

AGN

Allergan

$194.87

4.8821 (2.57%)

DLR

Digital Realty

$93.20

1.665 (1.82%)

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 12

    Dec

TIF Tiffany
$83.25

5.11 (6.54%)

11/23/16
OPCO
11/23/16
NO CHANGE
Target $87
OPCO
Outperform
Tiffany price target raised to $87 from $80 at Oppenheimer
Oppenheimer analyst Brian Nagel raised his price target for Tiffany to $87 from $80 ahead of results. While the analyst is concerned that a still challenged sales backdrop and higher expenses could weigh on results, longer term he is increasingly optimistic that internal merchandising and marketing efforts have the potential to fuel improved results, particularly as macro pressures potentially subside. Nagel reiterates an Outperform rating on the shares.
11/17/16
JEFF
11/17/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies sees 'robust' traffic at Tiffany flagship store amid Trump protests
After spending three days monitoring Tiffany's 5th Avenue flagship store in Manhattan to gauge traffic patterns and any Trump Tower protest related issues, Jefferies analyst Randal Konik concluded the store's traffic "was robust, not weak." Street police activity was high but didn't inhibit entrance to the store, Konik tells investors in a research note titled "5th Ave Flagship Store Checks Over Three Days Show 'Huuuuge' Strength." He believes investors are concerned that protests surrounding Trump Tower and high security will disrupt Tiffany's 5th Avenue store business. Konik keeps a Buy rating on Tiffany with a $100 price target.
11/14/16
JEFF
11/14/16
NO CHANGE
Target $100
JEFF
Buy
Tiffany price target raised to $100 from $85 at Jefferies
Jefferies analyst Randal Konik raised his price target for Tiffany to $100 saying the company has a strong positioning in a growing market. Fashion jewelry fundamentals are improving while tourism headwinds are abating, Konik tells investors in a research note. The analyst reiterates a Buy rating on the shares.
11/29/16
SBSH
11/29/16
NO CHANGE
Target $79
SBSH
Neutral
Citi keeps Neutral on Tiffany despite improvements in Q3
Citi analyst Paul Lejuez says that while Tiffany's Q3 results showed signs of improvement, he remains concerned over the company's ability to connect with the millennial customer in the U.S. He also believes the recent strengthening of the U.S. dollar could act as a headwind to Q4 and FY17. Lejuez expects Tiffany shares to trade higher today but he keeps a Neutral rating on the name with a $79 price target.
SYK Stryker
$116.17

3.22 (2.85%)

11/29/16
SBSH
11/29/16
UPGRADE
Target $108
SBSH
Neutral
Citi upgrades Zimmer to Neutral on Tom Price appointment
Citi analyst Amit Hazan upgraded Zimmer Biomet Holdings to Neutral saying the selection of Tom Price to head Health and Human Services "all but ensures current bundled payment programs may be significantly diluted." This removes a major risk to the U.S. reconstruction market, Hazan tells investors in a research note. He raised his price target for Zimmer shares to $108 from $95. The analyst keeps a Sell rating on Stryker (SYK).
11/01/16
BMOC
11/01/16
UPGRADE
BMOC
Market Perform
Stryker upgraded on positive catalysts at BMO Capital
As noted earlier, BMO Capital upgraded Stryker to Market Perform from Underperform. Analyst Joanne Wuensch says that the company's Q3 results were very strong, while the company's upcoming analyst event should alleviate investors' concerns. The analyst had previously expected the company to be hurt by the increased use of bundled payments, but she says that this has not materialized. Target $125.
11/01/16
BMOC
11/01/16
UPGRADE
BMOC
Market Perform
Stryker upgraded to Market Perform from Underperform at BMO Capital
10/31/16
PIPR
10/31/16
NO CHANGE
PIPR
Overweight
Zimmer Biomet pullback on earnings a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien noted that Zimmer Biomet (ZBH) reported "slightly weak" Q3 results and cut its guidance due to internal supply issues. However, he thinks the company should be able to re-engage customers and move closer to market growth next year after resolving the issues, which he expects it to fix in "probably" the next two quarters. Noting that the post-earnings decline puts Zimmer's value at a 31% discount to peer Stryker (SYK), which is much wider than average, the analyst points to the pullback as a buying opportunity and keeps an Overweight rating on Zimmer shares.
UNH UnitedHealth
$156.49

4.38 (2.88%)

11/09/16
BERN
11/09/16
NO CHANGE
BERN
Health insurers to see multiple catalysts from Trump presidency, says Bernstein
Bernstein analyst Lance Wilkes says that "repealing and replacing Obamacare will be Trump's primary focus." The analyst expects health insurers to benefit from from the repeal of ACA taxes and the elimination of requirements to spend a certain percentage of revenue on medical costs. Wilkes expects Anthem (ANTM) and Blue Cross/Blue Shield providers to benefit from the elimination of public exchanges and broad coverage requirements. Other health insurers include Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
10/19/16
LEER
10/19/16
NO CHANGE
Target $175
LEER
Outperform
UnitedHealth price target raised to $175 from $165 at Leerink
Leerink analyst Ana Gupte raised her price target for UnitedHealth to $175 from $165 after the company reported a "solid beat and raise" Q3, giving her more confidence in the strength of the company's diversified platform and execution while also offering positive read-across for Commercial Fully Insured & Individual fundamentals to the rest of the group. The analyst reiterates an Outperform rating on the shares.
11/09/16
MZHO
11/09/16
DOWNGRADE
Target $135
MZHO
Neutral
UnitedHealth downgraded to Neutral on Republican win at Mizuho
As previously reported, Mizuho analyst Sheryl Skolnick downgraded UnitedHealth to Neutral from Buy citing Donald Trump's election and the move to a GOP Congress. Following the election results, Skolnick sees an "extreme risk" for the ACA to be repealed and replaced and for the loss of the Medicaid expansion, both of which she notes have been primary drivers of results for hospitals and health plans. She cut her price target on the stock to $135 from $169.
11/09/16
MZHO
11/09/16
DOWNGRADE
MZHO
Neutral
UnitedHealth downgraded to Neutral from Buy at Mizuho
AGN Allergan
$194.87

4.8821 (2.57%)

11/21/16
11/21/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Brean Capital. 2. Allergan (AGN) initiated with a Market Perform at William Blair. 3. Myovant Sciences (MYOV) was initiated with an Overweight at Barclays, an Outperform at JMP Securities, an Outperform at Baird, a Buy at Citi, and an Outperform at Cowen. 4. RA Pharmaceuticals (RARX) was initiated with a Buy at Jefferies, a Buy at SunTrust, and an Outperform at Credit Suisse. 5. ZTO Express (ZTO) was initiated with a Buy ratings at Citi and Goldman and an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/23/16
JMPS
11/23/16
NO CHANGE
JMPS
Adamas could have positive read through from Allergan deal, says JMP Securities
After Adamas' partner, Allergan (AGN), agreed to buy Chase Pharmaceuticals, JMP Securities analyst Jason Butler thinks that the deal could have positive implications for Adamas Pharmaceuticals and its Alzheimer's treatment, Namzaric, a combination therapy which blocks a neutrotransmitter. The analyst says that the deal "reinforces Allergan's long-term commitment to neurotransmitter focused" Alzheimer;s treatments and provides the opportunity for Chase's drug to be combined with Namzaric. The analyst thinks that such a combined drug could gain additional market share. He keeps a $29 price target and an Outperform rating on Adamas.
11/04/16
UBSW
11/04/16
NO CHANGE
Target $240
UBSW
Buy
Allergan price target lowered to $240 from $300 at UBS
UBS analyst Marc Goodman lowered his price target on Allergan to $240 from $300 following disappointing Q3 results and a lowering of his estimates. However, Goodman reiterated his Buy rating on Allergan shares, on the belief it is still a good growth story, has an efficient tax structure and robust pipeline, and has the potential to put up double digit earnings growth for the rest of the decade.
11/21/16
WBLR
11/21/16
INITIATION
Target $209
WBLR
Market Perform
Allergan initiated with a Market Perform at William Blair
William Blair analyst Tim Lugo started Allergan with a Market Perform rating and $209 price target. The analyst views the company as high quality but sees headwinds in 2017 and 2018. Renewed competition for Botox could weigh on out-year estimates while a Namenda generic could come sooner than expected, Lugo tells investors in a research note.
DLR Digital Realty
$93.20

1.665 (1.82%)

11/08/16
MSCO
11/08/16
UPGRADE
MSCO
Overweight
Digital Realty upgraded to Overweight at Morgan Stanley (pre-open)
Pre-open, Morgan Stanley upgraded Digital Realty to Overweight from Equal Weight following the recent pullback in shares and raised its price target to $104 from $103 on shares.
09/28/16
BOFA
09/28/16
NO CHANGE
Target $120
BOFA
Buy
Digital Realty added to US 1 List at BofA/Merrill
BofA/Merrill added Digital Realty to the US 1 List based on secular growth in data center demand, its global footprint, valuation, and said it is a beneficiary of incremental capital flowing out of REITs and into data centers. Analyst Michael Funk rates Digital Realty a Buy with a $120 price target.
07/29/16
COWN
07/29/16
DOWNGRADE
COWN
Market Perform
Digital Realty downgraded to Market Perform from Outperform at Cowen
10/06/16
WELS
10/06/16
NO CHANGE
WELS
Interxion could be acquired for $45-$50 per share, says Wells Fargo
Wells Fargo says that Digital Realty's (DLR) recent moves indicate that it's interested in M&A. The firm continues to believe that Interxion "could be a key strategic fit for" Digital Realty, and Wells Fargo estimates that it could acquire Digital Realty for $45-$50 per share. Wells Fargo keeps Outperform ratings on InterXion and Digital Realty.

TODAY'S FREE FLY STORIES

VSR

Versar

$0.48

0.033 (7.33%)

07:44
09/25/17
09/25
07:44
09/25/17
07:44
Hot Stocks
Breaking Hot Stocks news story on Versar »

Versar trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$88.27

2.22 (2.58%)

07:44
09/25/17
09/25
07:44
09/25/17
07:44
Recommendations
Texas Instruments analyst commentary  »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$15.64

0.62 (4.13%)

07:42
09/25/17
09/25
07:42
09/25/17
07:42
Recommendations
Pure Storage analyst commentary  »

Pure Storage price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

PGR

Progressive

$47.98

0.3 (0.63%)

07:41
09/25/17
09/25
07:41
09/25/17
07:41
Recommendations
Progressive analyst commentary  »

Progressive outlook has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPC

Genuine Parts

$87.98

1.63 (1.89%)

07:41
09/25/17
09/25
07:41
09/25/17
07:41
Conference/Events
Genuine Parts to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 19

    Oct

  • 30

    Oct

TFX

Teleflex

$241.77

4.71 (1.99%)

07:41
09/25/17
09/25
07:41
09/25/17
07:41
Recommendations
Teleflex analyst commentary  »

Teleflex price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

BAS

Basic Energy

$17.24

-0.34 (-1.93%)

07:41
09/25/17
09/25
07:41
09/25/17
07:41
Recommendations
Basic Energy analyst commentary  »

Basic Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 16

    May

EONGY

E.ON AG

$11.19

0.2 (1.82%)

07:38
09/25/17
09/25
07:38
09/25/17
07:38
Periodicals
E.ON CFO defends plan to sell Uniper stake to Fortum, Reuters reports »

E.ON CFO Marc Spieker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$204.65

1.99 (0.98%)

07:36
09/25/17
09/25
07:36
09/25/17
07:36
Hot Stocks
Allergan announces resignation of CFO Tessa Hilado »

Allergan announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

WBC

Wabco

$150.14

0.95 (0.64%)

07:36
09/25/17
09/25
07:36
09/25/17
07:36
Initiation
Wabco initiated  »

Wabco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

FNV

Franco-Nevada

$79.32

0.4 (0.51%)

07:35
09/25/17
09/25
07:35
09/25/17
07:35
Downgrade
Franco-Nevada rating change  »

Franco-Nevada downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTN

Palatin

$0.66

0.06 (10.00%)

07:35
09/25/17
09/25
07:35
09/25/17
07:35
Earnings
Palatin reports Q4 EPS 7c, may not compare to consensus (2c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AAPL

Apple

$151.89

-1.5 (-0.98%)

, GE

General Electric

$24.87

0.12 (0.48%)

07:35
09/25/17
09/25
07:35
09/25/17
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

AAPL

Apple

$151.89

-1.5 (-0.98%)

GE

General Electric

$24.87

0.12 (0.48%)

ORCL

Oracle

$48.16

0.19 (0.40%)

M

Macy's

$21.53

0.37 (1.75%)

COP

ConocoPhillips

$49.08

0.39 (0.80%)

FCAU

Fiat Chrysler

$17.95

0.58 (3.34%)

WETF

WisdomTree

$9.25

0.23 (2.55%)

KBH

KB Home

$20.88

0.1 (0.48%)

MDR

McDermott

$7.01

0.1 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

  • 02

    Oct

  • 22

    Oct

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

07:33
09/25/17
09/25
07:33
09/25/17
07:33
Hot Stocks
Spark Therapeutics appoints Dr. Federico Mingozzi as Chief Scientific Officer »

Spark Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

AGN

Allergan

$204.65

1.99 (0.98%)

07:32
09/25/17
09/25
07:32
09/25/17
07:32
Hot Stocks
Allergan announces new $2B share repurchase plan, affirms guidance »

Allergan announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

ECA

Encana

$11.25

-0.05 (-0.44%)

07:31
09/25/17
09/25
07:31
09/25/17
07:31
Recommendations
Encana analyst commentary  »

Encana price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$204.65

1.99 (0.98%)

07:30
09/25/17
09/25
07:30
09/25/17
07:30
Hot Stocks
Breaking Hot Stocks news story on Allergan »

Allergan announces new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

EXAS

Exact Sciences

$45.96

0.96 (2.13%)

, ROK

Rockwell Automation

$177.55

0.22 (0.12%)

07:30
09/25/17
09/25
07:30
09/25/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

EXAS

Exact Sciences

$45.96

0.96 (2.13%)

ROK

Rockwell Automation

$177.55

0.22 (0.12%)

DVA

DaVita

$57.49

-3.77 (-6.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

NTDOY

Nintendo

$45.62

-0.98 (-2.10%)

, GOOG

Alphabet

$928.53

-3.92 (-0.42%)

07:29
09/25/17
09/25
07:29
09/25/17
07:29
Periodicals
Nintendo adds two-factor authentication for accounts, the Verge says »

Nintendo (NTDOY) users…

NTDOY

Nintendo

$45.62

-0.98 (-2.10%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 29

    Nov

EGO

Eldorado Gold

$2.26

0.02 (0.89%)

07:29
09/25/17
09/25
07:29
09/25/17
07:29
Upgrade
Eldorado Gold rating change  »

Eldorado Gold upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

APRN

Blue Apron

$5.19

-0.04 (-0.76%)

07:28
09/25/17
09/25
07:28
09/25/17
07:28
Initiation
Blue Apron initiated  »

Blue Apron initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$188.30

0.39 (0.21%)

07:27
09/25/17
09/25
07:27
09/25/17
07:27
Recommendations
Thermo Fisher analyst commentary  »

Thermo Fisher price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$51.60

4.8 (10.26%)

07:27
09/25/17
09/25
07:27
09/25/17
07:27
Recommendations
Cubic analyst commentary  »

Cubic price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLW

Corning

$30.05

-0.05 (-0.17%)

07:26
09/25/17
09/25
07:26
09/25/17
07:26
Periodicals
Corning looks to expand Gorilla presence in auto glass market, DigiTimes says »

Corning is looking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:26
09/25/17
09/25
07:26
09/25/17
07:26
General news
Futures pointing to slightly lower open »

Stock futures are trading…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.